Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

BeiGene, Ltd.

We are investigating BeiGene, Ltd. (BGNE) (“BeiGene” or the “Company”) for potential violations of the federal securities laws.

On September 5, 2019, J Capital Research (“J Capital”) published a report concerning BeiGene. The J Capital report asserted, inter alia, that BeiGene “is faking sales in order to persuade investors that it can develop a successful platform in China” and that “management may also be skimming R&D and capital budgets.” On this news, BeiGene’s American depositary receipt price fell $19.95 per share, or 14.19%, over the following two trading sessions, closing at $120.61 on September 6, 2019.